SCHEMBL22776571

SCHEMBL22776571

CN(CCc1ccc(Cn2cc(B3OC(C)(C)C(C)(C)O3)cn2)cc1)C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.47
USP30 Q70CQ3 2/20 0.39
BACE1 P56817 1/20 0.37
BACE2 Q9Y5Z0 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
UCHL1 P09936 1/20 0.36
SCD O00767 1/20 0.35
LPL P06858 1/20 0.34
LIPG Q9Y5X9 1/20 0.34
DGAT1 O75907 1/20 0.34
F2 P00734 1/20 0.34
F11 P03951 1/20 0.34
PRSS1 P07477 1/20 0.34
PRSS2 P07478 1/20 0.34
PRSS3 P35030 1/20 0.34
KLKB1 P03952 2/20 0.34
ESRRG P62508 1/20 0.34
AAK1 Q2M2I8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11908458 0.86 FFAR1 (0.54) FFAR1USP30BACE1BACE2UCHL1
SCHEMBL15092555 0.84 LIPG (0.49) USP30BACE1BACE2LPLLIPG
SCHEMBL19082801 0.82 FFAR1 (0.55) FFAR1USP30BACE1BACE2UCHL1
SCHEMBL22777159 0.80 FFAR1 (0.47) FFAR1UCHL1SCDLPLLIPG
SCHEMBL24117255 0.79 HDAC3 (0.57) FFAR1USP30HDAC3HDAC8NCOR2
SCHEMBL25826382 0.79 FFAR1 (0.46) FFAR1USP30BACE1BACE2DGAT1
SCHEMBL26598780 0.77 FFAR1 (0.60) FFAR1USP30BACE1BACE2UCHL1
SCHEMBL2562199 0.75 LIPG (0.48) USP30BACE1BACE2LPLLIPG
SCHEMBL30922325 0.74 FFAR1 (0.49) FFAR1UCHL1LPLLIPGF11
SCHEMBL30037522 0.74 FFAR1 (0.46) FFAR1USP30HDAC3HDAC8NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388566-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-12-25 US disclosed
US-12454520-B2 Protein degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-10-28 US disclosed
US-20230087825-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-23 US disclosed
EP-3817822-A1 PROTEIN DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-05-12 EP disclosed
WO-2020251969-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-17 WO disclosed
WO-2020251969-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230087825-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 FFAR1 4109/4885USP30 88/4885BACE1 1901/4885
US-12454520-B2 Protein degraders and uses thereof MDM2, CUL1, PSMG3 FFAR1 4335/4885USP30 47/4885BACE1 394/4885
US-20250388566-A1 PROTEIN DEGRADERS AND USES THEREOF SRR, SRRM2, CRBN FFAR1 3058/4885USP30 505/4885BACE1 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.